These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 28747060)

  • 21. Efficacy of switching to infliximab in patients with Crohn's disease with loss of response to adalimumab.
    Peeters H; Louis E; Baert F; Dewit O; Coche JC; Ferrante M; Lambrecht G; Colard A; Van Gossum A; Bossuyt P; Moreels T; Vander Cruyssen B; Gils A; De Vos M
    Acta Gastroenterol Belg; 2018; 81(1):15-21. PubMed ID: 29562373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing biological therapy in Crohn's disease.
    Gecse KB; Végh Z; Lakatos PL
    Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.
    Ward MG; Warner B; Unsworth N; Chuah SW; Brownclarke C; Shieh S; Parkes M; Sanderson JD; Arkir Z; Reynolds J; Gibson PR; Irving PM
    Aliment Pharmacol Ther; 2017 Jul; 46(2):150-161. PubMed ID: 28481014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous Versus Subcutaneous Anti-TNF-Alpha Agents for Crohn's Disease: A Comparison of Effectiveness and Safety.
    Liu J; Sylwestrzak G; Ruggieri AP; DeVries A
    J Manag Care Spec Pharm; 2015 Jul; 21(7):559-66. PubMed ID: 26108380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials.
    Panaccione R; Sandborn WJ; D'Haens G; Wolf DC; Berg S; Maa JF; Petersson J; Robinson AM
    J Crohns Colitis; 2018 Jul; 12(8):930-938. PubMed ID: 29697818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
    Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab-induced IgA nephropathy.
    Bhagat Singh AK; Jeyaruban AS; Wilson GJ; Ranganathan D
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30936328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
    Kaniewska M; Rosołowski M; Rydzewska G
    Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.
    Preda CM; Fulger LE; Negreanu L; Manuc M; Sandra I; Diculescu MM
    Rev Esp Enferm Dig; 2016 Oct; 108(10):642-647. PubMed ID: 27651132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies.
    Takahashi K; Fujimoto T; Shioya M; Nishida A; Bamba S; Inatomi O; Imaeda H; Kitoh K; Andoh A
    Clin J Gastroenterol; 2015 Apr; 8(2):88-91. PubMed ID: 25795267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
    Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
    J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of anti-TNFα drugs in patients with Crohn's disease who do not achieve remission with their first anti-TNFα agent.
    R-Grau Mdel C; Chaparro M; Mesonero F; Barreiro-de Acosta M; Castro L; Castro M; Domènech E; Mancenido N; Pérez-Calle JL; Taxonera C; Barrio J; De Francisco R; Fernández-Salgado E; Luzón L; Merino O; Oltra L; Saro C; Bermejo F; García-Sánchez V; Ginard D; Gutiérrez A; Vera I; Antón R; Ber Y; Calvet X; Gisbert JP
    Dig Liver Dis; 2016 Jun; 48(6):613-9. PubMed ID: 26992847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Findings of ulceration and severe stricture on MRE can predict prognosis of Crohn's disease in patients treated with anti-TNF treatment.
    Naganuma M; Okuda S; Hisamatsu T; Matsuoka K; Mori K; Hosoe N; Nakazato Y; Ogata H; Kanai T
    Abdom Radiol (NY); 2017 Jan; 42(1):141-151. PubMed ID: 27549100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome after a dose "de-intensification" strategy with anti-TNF drugs in patients with Crohn's disease.
    Chaparro M; Barreiro-de Acosta M; García-Planella E; Domènech E; Bermejo F; Calvet X; Martín Arranz MD; Monfort D; Gisbert JP
    Gastroenterol Hepatol; 2016 Apr; 39(4):255-60. PubMed ID: 26620278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity.
    Eder P; Katulska K; Krela-Kaźmierczak I; Stawczyk-Eder K; Klimczak K; Szymczak A; Linke K; Łykowska-Szuber L
    Abdom Imaging; 2015 Oct; 40(7):2210-8. PubMed ID: 26048698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
    Fumery M; Jacob A; Sarter H; Michaud L; Spyckerelle C; Mouterde O; Savoye G; Colombel JF; Peyrin-Biroulet L; Gower-Rousseau C; Turck D;
    J Pediatr Gastroenterol Nutr; 2015 Jun; 60(6):744-8. PubMed ID: 26000887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.